Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 220Rectal Neoplasms 137Stomach Neoplasms 95Colonic Neoplasms 87Pancreatic Neoplasms 82Esophageal Neoplasms 71Neoplasm Metastasis 58Squamous Cell Carcinoma of Head and Neck 43Head and Neck Neoplasms 42Adenocarcinoma Of Esophagus 37Neoplasms 36Breast Neoplasms 35Esophageal Squamous Cell Carcinoma 27Carcinoma, Hepatocellular 22Cholangiocarcinoma 21Adenocarcinoma 17Nasopharyngeal Carcinoma 16Bile Duct Neoplasms 14Gallbladder Neoplasms 13Carcinoma, Squamous Cell 13Biliary Tract Neoplasms 13Anus Neoplasms 13Urinary Bladder Neoplasms 11Liver Neoplasms 10Carcinoma 9Nasopharyngeal Neoplasms 8Colorectal Cancer Metastatic 8Peritoneal Neoplasms 7Recurrence 6Ovarian Neoplasms 6

Interventions

Oxaliplatin 2130-nm albumin-bound paclitaxel 2irinotecan sucrosofate 1folfirinox 1camrelizumab 1Surgical Procedures, Operative 1S 1 (combination) 1Leucovorin 1Gemcitabine 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Borderline Resectable Pancreatic Cancer × Fluorouracil × Clear all
NCT06345300 2024-04-03

NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Unknown
40 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡